智通财经APP获悉，同源康医药-B(02410)盘中涨超12%，截至发稿，涨7.16%，报14.21港元，成交额1.32亿港元。
消息面上，在今年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺癌脑转移关键Ⅱ期临床试验引起同行高度关注。据悉，艾多替尼片（TY-9591）是同源康医药针对EGFR经典突变开发的高选择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月提交预上市（Pre-NDA）申请，预计2025年4季度正式提交附条件上市（NDA）申请。
太平洋证券此前指，三代EGFR-TKI药物已经成为肺癌靶向治疗的基石药物，现在药物研发已经非常火热。患者后续依旧面临着EGFR-TKI耐药的问题，耐药后的解决方案将会更具备投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.